Al-Ibraheem Akram, Scott Andrew M
Department of Nuclear Medicine and PET/CT, King Hussein Cancer Center (KHCC), P.O. Box 1269, Al-Jubeiha, Amman, 11941 Jordan.
Department of Radiology and Nuclear Medicine, Division of Nuclear Medicine, University of Jordan, Amman, 11942 Jordan.
Nucl Med Mol Imaging. 2023 Aug;57(4):168-171. doi: 10.1007/s13139-023-00804-7. Epub 2023 Apr 26.
Radiotheranostics with Lu-PSMA have changed the treatment paradigm in patients with prostate cancer, becoming the new standard in certain settings. Terbium-161 (Tb) has been recently investigated as a potential radionuclide for radiotheranostics in various types of cancer, including metastatic castration-resistant prostate cancer (mCRPC). The nuclear medicine team at King Hussein Cancer Center (KHCC) in Amman, Jordan, recently published the first-in-human SPECT/CT imaging results following a well-tolerated dose of Tb-PSMA radioligand therapy with no treatment-related adverse events, adding to the potential of radiotheranostics in prostate cancer. Two clinical trials for Tb-PSMA radioligand therapy in prostate cancer are currently underway and will provide valuable insights. This review will shed light on the expanding field of radiotheranostics in prostate cancer, which is not without challenges, and will discuss how the introduction of a new therapeutic option like Tb-PSMA may help to combat these challenges and build on the proven success of Lu-PSMA-based radiotheranostics for the benefit of prostate cancer patients worldwide.
镥-PSMA放射性核素治疗诊断学改变了前列腺癌患者的治疗模式，在某些情况下成为新标准。铽-161（Tb）最近被研究作为各种癌症，包括转移性去势抵抗性前列腺癌（mCRPC）放射性核素治疗诊断学的潜在放射性核素。约旦安曼侯赛因国王癌症中心（KHCC）的核医学团队最近公布了首例人体单光子发射计算机断层扫描/计算机断层扫描（SPECT/CT）成像结果，在给予耐受良好的Tb-PSMA放射性配体治疗剂量后，未出现与治疗相关的不良事件，这增加了放射性核素治疗诊断学在前列腺癌中的潜力。目前正在进行两项关于Tb-PSMA放射性配体治疗前列腺癌的临床试验，将提供有价值的见解。本综述将阐明前列腺癌放射性核素治疗诊断学这一不断扩展的领域，该领域并非没有挑战，并将讨论引入像Tb-PSMA这样的新治疗选择如何有助于应对这些挑战，并在基于镥-PSMA的放射性核素治疗诊断学已证实的成功基础上再接再厉，造福全球前列腺癌患者。
